Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,947 | 9,122 | 7,011 | 10,583 | 34,128 |
| Marketable Securities | 18,126 | 17,106 | 22,075 | 22,028 | N/A |
| Receivables | 734 | 585 | 676 | 274 | 347 |
| TOTAL | $23,807 | $26,813 | $29,762 | $32,885 | $34,475 |
| Non-Current Assets | |||||
| PPE Net | 81 | 75 | 74 | 60 | 55 |
| Investments And Advances | 33 | 11 | 11 | 9 | 10 |
| TOTAL | $114 | $86 | $85 | $69 | $65 |
| Total Assets | $23,921 | $26,899 | $29,847 | $32,954 | $34,540 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,762 | 1,736 | 1,739 | 2,280 | 1,146 |
| TOTAL | $1,762 | $1,736 | $1,739 | $2,280 | $1,146 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 51 | 32 | 13 | 0 | 0 |
| TOTAL | $51 | $32 | $13 | $N/A | $N/A |
| Total Liabilities | $1,813 | $1,768 | $1,752 | $2,280 | $1,146 |
| Shareholders' Equity | |||||
| Common Shares | 39 | 39 | 39 | 39 | 39 |
| Retained earnings | -18,958 | -15,407 | -11,721 | -8,422 | -5,271 |
| TOTAL | $22,108 | $25,131 | $28,095 | $30,674 | $33,394 |
| Total Liabilities And Equity | $23,921 | $26,899 | $29,847 | $32,954 | $34,540 |